<DOC>
	<DOCNO>NCT02776761</DOCNO>
	<brief_summary>This single-center , randomize , single-blinded study HTNV DNA vaccine alone , PUUV DNA vaccine alone , mixed HTNV/PUUV DNA vaccine deliver IM needle-free PharmaJet Stratis DSJI device .</brief_summary>
	<brief_title>A Single-blind Study Evaluate Safety , Tolerability , Immunogenicity Hantaan Virus DNA Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy adult male nonpregnant , nonlactating female , age 1849 ( inclusive ) time screen Have provide write informed consent screen Free clinically significant health problem determine pertinent medical history clinical examination prior entry study Available able participate study visit procedure Females , abstinent , know least 1 year postmenopausal ( defined menses 12 consecutive month ) willing use effective method contraception ( eg , hormonal contraception include oral implantable option , diaphragm , cervical cap , intrauterine device , condom , anatomical sterility [ self partner ] ) duration study participation ( date screening ) least 3 month last injection Negative hantavirus PsVNA test result screen History serologic evidence prior infection hantavirus prior participation HTNV PUUV vaccine trial History severe local systemic reaction vaccination history severe allergic reaction Ongoing participation another clinical trial ( subject continue Day 365 join new study final visit ) Receipt license vaccine within 14 day immunization ( 30 day live vaccine ) Ability observe possible local reaction eligible injection site ( deltoid region ) , opinion investigator , unacceptably obscure due physical condition permanent body art Acute chronic , clinically significant hematologic , pulmonary , cardiovascular , hepatic renal functional abnormality determine investigator base medical history , physical exam , and/or laboratory screen test Pregnant lactate female , female intend become pregnant study period Administration immunoglobulins and/or blood product within 120 day precede study entry plan administration study period Blood donation human use ( eg , American Red Cross similar blood drive ) within 56 day precede study entry plan administration study period Any confirm evidence hepatitis B C infection Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection Administration chronic ( defined 14 day ) immunosuppressant immunemodifying drug within 6 month study entry For corticosteroid , mean prednisone , equivalent , great equal 0.5 mg/kg/day Intranasal , inhale , topical steroid allow ( daily inhale steroid treatment asthma NOT allow ) Any chronic active neurologic disorder , include seizure epilepsy , exclude single febrile seizure child Suspected known current alcohol and/or illicit drug abuse Unwilling allow storage use blood future hantavirusrelated research Any significant finding opinion investigator would increase risk individual adverse outcome participating study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>